Article
Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target.
Nature communications - 19 Apr 2018
Dufva Olli, Kankainen Matti, Kelkka Tiina, Sekiguchi Nodoka, Awad Shady Adnan, Eldfors Samuli, Yadav Bhagwan, Kuusanmäki Heikki, Malani Disha, Andersson Emma I, Pietarinen Paavo, Saikko Leena, Kovanen Panu E, Ojala Teija, Lee Dean A, Loughran Thomas P, Nakazawa Hideyuki, Suzumiya Junji, Suzuki Ritsuro, Ko Young Hyeh, Kim Won Seog, Chuang Shih-Sung, Aittokallio Tero, Chan Wing C, Ohshima Koichi, Ishida Fumihiro, Mustjoki Satu
Abstract excerpt
Aggressive natural killer-cell (NK-cell) leukemia (ANKL) is an extremely aggressive malignancy with dismal prognosis and lack of targeted therapies. Here, we elucidate the molecular pathogenesis of ANKL using a combination of genomic and drug sensitivity profiling. We study 14 ANKL patients using whole-exome sequencing (WES) and identify mutations in STAT3 (21%) and RAS-MAPK pathway genes (21%) as well as in...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.